February 9, 2022 -- Congruence Therapeutics closed a $50 million, tranched, series A financing round to deploy its computational platform for rational drug design and to build a database of mutant proteins.
The cornerstone of Congruence's strategy is Revenir, a tool for the rational design of stabilizers that circumvents the target validation, protein purification, and high-throughput-screening stages. The technology uses mathematical modeling, physics, and machine learning to characterize the biophysical defects of misfolded proteins that cause disease and then designs compounds to rescue the mutated proteins by correcting these defects in silico, the company said.
Congruence is currently deploying Revenir in indications with high unmet medical needs. It is also building a proprietary database containing the biophysical properties of mutant proteins, which can be used to develop stabilizers for diseases caused by protein families.
Congruence Therapeutics is a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.
The financing was led by Amplitude Ventures and Fonds de solidarité FTQ, with participation from Lumira Ventures, Investissement Québec, OrbiMed Advisors, Driehaus Capital Management, and others.